All Stories

  1. Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
  2. Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
  3. Corrigendum to “Prevalence of mental health conditions and brain fog in people with long COVID: A systematic review and meta-analysis” [General Hospital Psychiatry volume 88 (2024)10–22 10.1016/j.genhosppsych.2024.02.009]
  4. Exploring the help-seeking journeys for Long Covid from a health inequalities perspective: a qualitative study in England
  5. Incidence of diabetes mellitus following hospitalisation for COVID ‐19 in the United Kingdom: A prospective observational study
  6. Exploring Histoplasma species seroprevalence and risk factors for seropositivity in The Gambia’s working equid population: Baseline analysis of the Tackling Histoplasmosis project dataset
  7. Cognitive and psychiatric symptom trajectories 2–3 years after hospital admission for COVID-19: a longitudinal, prospective cohort study in the UK
  8. 1-year health outcomes associated with systemic corticosteroids for COVID-19: a longitudinal cohort study
  9. HAP-FAST: a feasibility study incorporating qualitative, mechanistic and costing sub-studies alongside a randomised pilot trial comparing chest x-ray to low-dose CT scan and empirical antibiotics to antibiotics guided by the BIOFIRE® FILM ARRAY® pneumo...
  10. Histoplasma seropositivity and environmental risk factors for exposure in a general population in Upper River Region, The Gambia: A cross-sectional study
  11. Risk of Cardiovascular Events after Acute Exacerbations of Chronic Obstructive Pulmonary Disease in Patients Receiving Long-Term Low-Dose Azithromycin
  12. Low-dose azithromycin prophylaxis in patients with atrial fibrillation and chronic obstructive pulmonary disease
  13. Prevalence of mental health conditions and brain fog in people with long COVID: A systematic review and meta-analysis
  14. Author Correction: Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses
  15. Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease
  16. Barriers to healthcare access and experiences of stigma: Findings from a coproduced Long Covid case‐finding study
  17. Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial
  18. Accelerated immune ageing is associated with COVID-19 disease severity
  19. Barriers to healthcare access: findings from a co-produced Long Covid case-finding study
  20. Effect of second booster vaccinations and prior infection against SARS-CoV-2 in the UK SIREN healthcare worker cohort
  21. Residual Lung Abnormality Following COVID-19 Hospitalisation is Characterised by Epithelial Injury
  22. Delayed Mucosal Antiviral Responses Despite Robust Peripheral Inflammation in Fatal COVID-19
  23. Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses
  24. Cohort Profile: Post-Hospitalisation COVID-19 (PHOSP-COVID) study
  25. Large scale phenotyping of long COVID inflammation reveals mechanistic subtypes of disease after COVID-19 hospitalisation
  26. Clinical trials of pneumonia management assess heterogeneous outcomes and measurement instruments
  27. Pathways to care for Long COVID and for long‐term conditions from patients' and clinicians' perspective
  28. One year health outcomes associated with systemic corticosteroids for COVID-19: a longitudinal cohort study
  29. Long COVID research: an update from the PHOSP-COVID Scientific Summit
  30. Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study
  31. Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
  32. Histoplasma Seropositivity in TB Patients in The Gambia: Evidence to Drive Research on a High-Priority Fungal Pathogen
  33. Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history
  34. Long Covid active case finding study protocol: A co-produced community-based pilot within the STIMULATE-ICP study (Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Transform Existing Integrated Care Pathways)
  35. SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease
  36. Prevalence of swallow, communication, voice and cognitive compromise following hospitalisation for COVID-19: the PHOSP-COVID analysis
  37. Large scale phenotyping of long COVID inflammation reveals mechanistic subtypes of disease
  38. Determinants of recovery from post-COVID-19 dyspnoea: analysis of UK prospective cohorts of hospitalised COVID-19 patients and community-based controls
  39. Cohort Profile: Post-hospitalisation COVID-19 study (PHOSP-COVID)
  40. Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study
  41. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
  42. The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection
  43. Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study
  44. Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens
  45. Multi-organ impairment and long COVID: a 1-year prospective, longitudinal cohort study
  46. Outcome of COVID-19 in hospitalised immunocompromised patients: An analysis of the WHO ISARIC CCP-UK prospective cohort study
  47. Omicron BA.1/BA.2 infections in triple-vaccinated individuals enhance a diverse repertoire of mucosal and blood immune responses
  48. The effects of sleep disturbance on dyspnoea and impaired lung function following COVID-19 hospitalisation: a prospective multi-centre cohort study
  49. Residual Lung Abnormalities Following COVID-19 Hospitalization: Interim Analysis of the UKILD Post-COVID Study
  50. SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination
  51. STIMULATE-ICP-Delphi study to inform integrated care pathways for Long COVID.
  52. Viral Coinfections in Hospitalized Coronavirus Disease 2019 Patients Recruited to the International Severe Acute Respiratory and Emerging Infections Consortium WHO Clinical Characterisation Protocol UK Study
  53. Nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination
  54. Long Covid active case finding: a co-produced community-based pilot within the STIMULATE-ICP study (Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Transform Existing Integrated Care Pathways)
  55. STIMULATE-ICP-CAREINEQUAL (Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Transform Existing Integrated Care Pathways) study protocol: Defining usual care and examining inequalities in Long Covid support
  56. Outcome of COVID-19 in hospitalised immunocompromised patients: an analysis of the WHO ISARIC CCP-UK prospective cohort study
  57. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study
  58. Device-assessed sleep and physical activity in individuals recovering from a hospital admission for COVID-19: a multicentre study
  59. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
  60. Evolution of long-term vaccine induced and hybrid immunity in healthcare workers after different COVID-19 vaccination regimens: a longitudinal observational cohort study
  61. STIMULATE-ICP-CAREINEQUAL - Defining usual care and examining inequalities in Long Covid support: protocol for a mixed-methods study (part of STIMULATE-ICP: Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Tran...
  62. Comparison of two T-cell assays to evaluate T-cell responses to SARS-CoV-2 following vaccination in naïve and convalescent healthcare workers
  63. STIMULATE-ICP-Delphi (Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Transform Existing Integrated Care Pathways Delphi): Study protocol
  64. Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study
  65. Multi-organ impairment and Long COVID: a 1-year prospective, longitudinal cohort study
  66. Interstitial lung damage following COVID-19 hospitalisation: an interim analysis of the UKILD Post-COVID study
  67. Comparison of two T cell assays to evaluate T cell responses to SARS-CoV-2 following vaccination in naïve and convalescent healthcare workers
  68. Device-assessed sleep and physical activity in individuals recovering from a hospital admission for COVID-19: a prospective, multicentre study
  69. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
  70. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
  71. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
  72. T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study
  73. Clinical characteristics with inflammation profiling of Long-COVID and association with one-year recovery following hospitalisation in the UK: a prospective observational study
  74. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study
  75. The impact of viral mutations on recognition by SARS-CoV-2 specific T cells
  76. Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
  77. Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID)
  78. Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study
  79. Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study
  80. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
  81. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
  82. A rapid assessment of wastewater for genomic surveillance of SARS-CoV-2 variants at sewershed scale in Louisville, KY
  83. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study
  84. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
  85. Prognostic Indicators and Outcomes of Hospitalised COVID-19 Patients with Neurological Disease: A Systematic Review and Individual Patient Data Meta-Analysis
  86. Co-Infections, Secondary Infections, and Antimicrobial Usage in Hospitalised Patients with COVID-19 from the ISARIC WHO CCP-UK Study: A Prospective, Multicentre Cohort Study
  87. Utility of established prognostic scores in COVID-19 hospital admissions: multicentre prospective evaluation of CURB-65, NEWS2 and qSOFA
  88. The utility of established prognostic scores in COVID-19 hospital admissions: a multi-centre prospective evaluation of CURB-65, NEWS2, and qSOFA
  89. The challenge of antimicrobial prescribing for hospital-acquired pneumonia
  90. Antimicrobial prescribing for hospital-acquired pneumonia
  91. Community‐acquired pneumonia due to drug‐resistantEnterobacteriaceae: A global perspective
  92. A Haemophilus sp. dominates the microbiota of sputum from UK adults with non-severe community acquired pneumonia and chronic lung disease
  93. Quantification of Efferocytosis by Single-cell Fluorescence Microscopy
  94. A longitudinal modelling study estimates acute symptoms of community acquired pneumonia recover to baseline by 10 days
  95. Recovery from pneumonia requires efferocytosis which is impaired in smokers and those with low body mass index and enhanced by statins
  96. Correction
  97. Household Air Pollution Causes Dose-Dependent Inflammation and Altered Phagocytosis in Human Macrophages
  98. Blinded randomised controlled trial of low-dose Adjuvant Steroids in Adults admitted to hospital with Pandemic influenza (ASAP): a trial ‘in hibernation’, ready for rapid activation
  99. The diagnosis of pneumonia requires a chest radiograph (x-ray) – yes, no or sometimes?
  100. Bronchoalveolar Lavage (BAL) for Research; Obtaining Adequate Sample Yield
  101. The pathophysiology of pneumococcal pneumonia
  102. Feasibility study for early supported discharge in adults with respiratory infection in the UK
  103. Supported home-care schemes: the key to increasing outpatient care?
  104. Using the BTS CAP audit to evaluate local data
  105. Pharmacokinetics of chlorproguanil, dapsone, artesunate and their major metabolites in patients during treatment of acute uncomplicated Plasmodium falciparum malaria
  106. Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi
  107. Open-Label Comparative Clinical Study of Chlorproguanil−Dapsone Fixed Dose Combination (Lapdap™) Alone or with Three Different Doses of Artesunate for Uncomplicated Plasmodium falciparum Malaria
  108. Malaria: clinical features and recommended management